Beijing ZhongShuo Pharmaceutical Technology Development Co.,Ltd.

Company Profile
Beijing ZhongShuo Pharmaceutical Technology Development Co.,Ltd.
Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd. was established in February 2001. Formerly a wholly-owned subsidiary of Sinopharm Group China Pharmaceutical Industry Corporation. Beijing Zhongshuo Pharmaceutical is a high-tech enterprise with chemical drug research and development as its core, specializing in the research and development, production, sales and technology transfer of chemical API’s, pharmaceutical intermediates and preparations. Beijing Zhongshuo Pharmaceutical has a sales company and 3,000 square meters of research and development center in Beijing, with a research and development team of more than 100 people, including drug synthesis, drug analysis, drug preparation three platforms. In Changzhi City, Shanxi Province has a cooperative production plant, the production capacity of API intermediates is one hundred tons per year. The main business of Beijing Zhongshuo Pharmaceutical is: production and supply of high-end generic drug starting materials; R&D, registration and application, technology transfer of high-end generic drug apis and preparations; Small molecule, bioinnovative drug CDMO; Cosmetics new raw materials registration, efficacy evaluation. Good reaction types include nitrification, sulfonation, chlorination, bromination, hydrogenation, high temperature, ultra-low temperature, alkylation, diazotization, various REDOX, format, etc. The main products of Beijing Zhongshuo Pharmaceutical is: Vonorazan Fumarate; Tegoprazan; Deucravacitinib; Upatinib; Mabaloxavir; Creborol; Posaconazole; Simaglutide; Tirzepatide; Linaclotide; Alarelin Acetate; Octreotide Acetate; Leuprorelin Acetate; Eptifibatide; Atosiban Acetate; Teriparatide; Aviptadil Acetate; Abaloparatide; Tetracosactide Acetate;Pramlintide; Teduglutide; Deslorelin Acetate; Sermorelin Acetate; SLANK; Cagrilintide; FOXO4-DRI; Thymosin α1; Thymosin β-4; Emideltide; Lixisenatide Acetate; Retatrutide; Amitriptyline Hydrochloride; Triptorelin Acetate; Duloxetine Hydrochloride; Sitagliptin Phosphate Monohydrate; Cabatasel; Pirubicin; Idarubicin Hydrochloride; Micafungin Sodium; Retinol; Mu-conotoxin; Relebactam; Olopatadine Hydrochloride; Ibrutinib; Bugtinib; Ropotrectinib; ADC drugs linker, etc.
more >

Year of Establishment: 2002

Total Assets(USD): choose not to disclose

Total Number of Staff: less than 10 person

Main Competitive Advantages:

Other Competitive Advantages:

Patents and Copyrights:

Send your message to this supplier
  • From:
  • To:
    Beijing ZhongShuo Pharmaceutical Technology Development Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service